Study Ties Pfizer Anti-Smoking Drug To Heart Problems

Law360, New York (July 5, 2011, 1:22 PM EDT) -- Pfizer Inc.'s smoking cessation drug Chantix has been linked to serious cardiovascular problems, such as congestive heart failure and stroke, according to an analysis published by a Canadian medical journal on Monday.

The analysis of 14 double-blind trials involving 8,216 participants published by the Canadian Medical Association Journal revealed a 72 percent increased risk of serious cardiovascular problems for those who took varenicline, the main ingredient in Chantix, compared to a placebo.

The analysis comes after the U.S. Food and Drug Administration reported in June that...
To view the full article, register now.